CalciMedica, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CalciMedica, Inc. (CALC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 732.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 732.50K shares, a 62.62% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 70.94K shares, a 29.06% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 34.50K shares, a 94.20% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.10M shares, a 58.32% increase from fiscal 2024.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.33M shares, a 68.78% increase from fiscal 2023.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 785.92K shares, a 36.63% decline from fiscal 2022.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.24M shares, a 24.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 732.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 732.50K shares 10-Q · filed 2026-08-11 | 803.44K shares derived: sum of 3 quarters · filed 2026-08-11 | 837.94K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | 70.94K shares derived: sum of 2 quarters · filed 2026-05-12 | 105.44K shares derived: sum of 3 quarters · filed 2026-05-12 | 2.07M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 70.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 105.44K shares derived: sum of 2 quarters · filed 2026-03-03 | 2.07M shares derived: sum of 3 quarters · filed 2026-03-03 | 2.10M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 34.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.99M shares derived: sum of 2 quarters · filed 2025-11-12 | 2.03M shares 10-Q · filed 2025-11-12 | 2.13M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.96M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.99M shares 10-Q · filed 2025-08-12 | 2.09M shares derived: sum of 3 quarters · filed 2025-08-12 | 2.69M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 35.00K shares 10-Q · filed 2025-05-14 | 135.00K shares derived: sum of 2 quarters · filed 2025-05-14 | 730.25K shares derived: sum of 3 quarters · filed 2025-05-14 | 766.25K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 100.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 695.25K shares derived: sum of 2 quarters · filed 2025-03-27 | 731.25K shares derived: sum of 3 quarters · filed 2025-03-27 | 1.33M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 595.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 631.25K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.23M shares 10-Q · filed 2024-11-13 | 1.23M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 36.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 631.25K shares 10-Q · filed 2024-08-12 | 631.25K shares derived: sum of 3 quarters · filed 2024-08-12 | 631.25K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 595.25K shares 10-Q · filed 2024-05-13 | 595.25K shares derived: sum of 2 quarters · filed 2024-05-13 | 595.25K shares derived: sum of 3 quarters · filed 2024-05-13 | 1.20M shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-28 | 605.69K shares derived: sum of 3 quarters · filed 2024-03-28 | 785.92K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 605.69K shares derived: sum of 2 quarters · filed 2023-11-09 | 785.92K shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 605.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 785.92K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 180.23K shares 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | 1.24M shares 10-K · filed 2023-03-09 | |||
| 2021-12-31 | 1.65M shares 10-K · filed 2022-03-11 | |||
| 2020-12-31 | 1.10M shares 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |